References in periodicals archive ?
The platforms are activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF).
The preclinical stage drug candidate AL-309 is derived from ADNF and is being developed for the treatment of peripheral neuropathies.
Protection against the physical effects of alcohol exposure also has been observed with administration of a variety of neurotrophic factors, including BDNF, IGF-I, NGF, and neuropeptides derived from activity-dependent neurotrophic factor (ADNF) and activity-dependent neurotrophic peptide (ADNP), as well as their small peptide active fragments SAL and NAP, to name a few.